Use of immunosuppressive medications and prevalence of disability among patients with pediatric systemic lupus erythematosus: initial analysis of the CARRAnet registry

Emily von Scheven(Unknown), Mary Beth F. Son(Boston Children's Hospital), Hermine I. Brunner(Cincinnati Children's Hospital Medical Center), Aimee O. Hersh(University of Utah), B. Anne Eberhard(Hofstra University)

Pediatric Rheumatology

July 1, 2012

10.1186/1546-0096-10-s1-a28

Cited by 0

Related Papers

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

|New England Journal of Medicine|2020|2.7k

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

|JAMA|2021|852

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1

|Arthritis & Rheumatology|2020|537

Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series

|Arthritis & Rheumatism|2010|465

Transancestral mapping and genetic load in systemic lupus erythematosus

|Nature Communications|2017|436